Nanjing Leads Biolabs Sets Up Audit Committee to Strengthen Corporate Governance

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has provided an update.

Nanjing Leads Biolabs Co., Ltd. has established an audit committee under its board of directors to strengthen internal control, enhance corporate governance, and ensure effective supervision of its financial reporting and risk management. The committee, composed entirely of non-executive directors with a majority of independent non-executive directors including at least one member with professional accounting or financial expertise, is tasked with reviewing the company’s financial condition and information, overseeing internal and external audits, evaluating internal control systems and major investment risks, and exercising powers equivalent to a supervisory committee, thereby tightening governance standards and aligning the company more closely with Hong Kong listing and corporate governance requirements.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a China-based company listed in Hong Kong, operating under the PRC Company Law and the Hong Kong Listing Rules, with a governance framework aligned to the Corporate Governance Code and other regulatory guidelines. The company emphasizes strong internal controls, transparent financial reporting, and compliance with international best practices, reflecting a focus on investor confidence and robust corporate governance in its market operations.

Average Trading Volume: 594,245

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$9.63B

Learn more about 9887 stock on TipRanks’ Stock Analysis page.